Literature DB >> 2457134

A hybrid ligand method for androgen receptor measurement.

W S Stebbings1, E Anderson, J R Puddefoot, M J Farthing, G P Vinson.   

Abstract

Existing techniques for androgen receptor (AR) assay are complicated by cross-reactivity of ligand binding affinities that can lead to incorrect estimation of receptor concentration. Two most frequently used ligands are [3H]dihydrotestosterone [( 3H]DHT) and [3H]methyltrienolone [( 3H]R1881), which in addition to binding to AR also bind to sex hormone binding globulin (SHBG; Kd = 1.5 nM) and progesterone receptors (PgR; Human Kd = 1 nM, rat Kd = 6 nM) respectively. Triamcinolone acetonide (TMA) is commonly used to block binding of [3H]R1881 to PgR, however at high concentrations TMA itself will bind AR (Kd = 7 microM). We have developed a hybrid ligand method for the measurement of AR in the presence of SHBG and PgR. This method used [3H]R1881 as the high specific activity labelled tracer and DHT as the unlabelled competitor of specific AR binding. Using this assay, 20% of human colorectal carcinomas were found to contain AR.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2457134     DOI: 10.1016/0022-4731(88)90052-0

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  3 in total

1.  Androgen receptors in colorectal adenomas.

Authors:  W S Stebbings; M J Farthing; J R Puddefoot; E Anderson; G P Vinson; J M Northover; R F Wood
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

2.  Effect of steroid hormones on human colorectal adenocarcinoma xenografts, of known steroid-receptor status, in nude mice.

Authors:  W S Stebbings; G P Vinson; M J Farthing; F Balkwill; R F Wood
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

3.  Clinicopathological and prognostic significance of androgen receptor overexpression in colorectal cancer. Experience from Al-Madinah Al-Munawarah, Saudi Arabia.

Authors:  Abdulkader M Albasri; Mohammed A Elkablawy
Journal:  Saudi Med J       Date:  2019-09       Impact factor: 1.484

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.